Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address
treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive …

Disease outcomes of HER2+ breast cancers have dramatically improved after targeted
therapies, such as trastuzumab became available. The main mechanism of action of …

The goal of this study is to develop an integrated, mathematical–experimental approach for
understanding the interactions between the immune system and the effects of trastuzumab …

Background: HER2 positive Breast Cancers (BC) have aggressive behavior and poor
prognosis. Previously, we have identified miR-342-5p as an upstream regulator of HER2 …

Background: Patients with early stage breast cancer with lymph nodes metastasis were
proven to have more aggressive biologically phenotypes. This study aimed to build a …

Purpose We evaluated the effect of younger age on recurrence risk in Chinese women
diagnosed with T1N0M0 breast cancer (BC), using propensity score matching (PSM) …

Abstract Objectives Patients with T1N0M0 breast cancers are considered to have an
excellent prognosis, even in triple-negative breast cancer (TNBC), which is often associated …

Abstract Purpose GEICAM/2006–10 compared anastrozole (A) versus fulvestrant plus
anastrozole (A+ F) to test the hypothesis of whether a complete oestrogen blockade is …